Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency virus (HIV), a discovery that brings medical experts one step closer to a cure ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations.

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025IMC-M113V was well ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

To become infectious, HIV has to undergo a maturation process, which involves a rearrangement of the matrix proteins (red). In an immature virus particle, the matrix proteins form a lose lattice ...

Lenacapavir is a twice-yearly injectable human immunodeficiency virus-1 (HIV-1) capsid inhibitor intended to prevent HIV as pre-exposure prophylaxis (PrEP). The latest announcement follows the recent ...

A Chinese team of virologists has found that this virus carries the risk of animal-to-human transmission. According to the South China Morning Post (SCMP), the new virus called HKU5-CoV-2 was ...

Antiretroviral drugs are used to treat HIV infection. They work by blocking a stage of the virus's life cycle and, by doing so, prevent the virus from replicating. The drugs are organized into six ...

"Other viruses unrelated to Zika, such as HIV, herpes, influenza A and SARS-CoV-2, the virus that causes COVID-19, also can induce tiny tunnels in cells they infect and use the tunnels to spread ...